Altay Therapeutics
Altay Therapeutics (Altay) is developing small molecule therapies to treat chronic inflammation and cancers by targeting disease-causing transcription factors. Preliminary data of the lead candidate, PCE1911, has been shown to treat Ewing’s Sarcoma. Further, mouse data on the second candidate, E46, has been shown to pr
Operating in health based in San Francisco, CA, USA; South San Francisco, CA, USA, Altay Therapeutics operates.
Profile
Altay Therapeutics (Altay) is developing small molecule therapies to treat chronic inflammation and cancers by targeting disease-causing transcription factors. Preliminary data of the lead candidate, PCE1911, has been shown to treat Ewing’s Sarcoma. Further, mouse data on the second candidate, E46, has been shown to prevent and reverse lung fibrosis.
As a business in health, Altay Therapeutics is listed here with the public details available about it.
The company is recorded as being based in San Francisco, CA, USA; South San Francisco, CA, USA.
The company is listed at the Winter 2020 stage of development.
Recorded headcount: 6 employees.
| Sector | Health |
|---|---|
| Headquarters | San Francisco, CA, USA; South San Francisco, CA, USA |
| Country | USA |
| Employees | 6 |
| Stage | Winter 2020 |
Website: www.altaytherapeutics.com
Browse related
Create a free account